---

Market Overview

---

The global endoscopic imaging systems market was valued at $3,641 million in 2021 and is projected to grow at a CAGR of 7.43% to reach $6,941 million by 2030. This growth can be attributed to several factors, including the increasing adoption of minimally invasive procedures, advancements in the quality of endoscopic procedures, and the integration of technology into endoscopic imaging systems.

The demand for minimally invasive procedures is driving the advancements in endoscopy and increasing its adoption among physicians and other end users. These procedures offer several benefits such as reduced post-operative complications, faster recovery times, and shorter hospital stays. As a result, there is a growing demand for endoscopic imaging systems that support these procedures.

The use of artificial intelligence (AI) in endoscopic procedures presents a significant opportunity for market growth. AI can assist in real-time image analysis, lesion detection, and pathology identification, thereby improving the accuracy and efficiency of endoscopic procedures. Additionally, the entry of local companies into regional markets is another opportunity for growth, as it promotes competition and innovation.

Developing regions also present an opportunity for market expansion, as there is an increasing demand for endoscopic imaging systems in these areas. However, there are challenges that need to be addressed. The lack of skilled professionals who can perform endoscopic procedures is a limitation to market growth. Training programs and initiatives should be implemented to bridge this gap and ensure the availability of skilled personnel.

Another challenge is the lack of a reimbursement system in developing countries. Without proper reimbursement, healthcare providers may hesitate to invest in expensive endoscopic imaging systems, hindering market growth in these regions. Efforts should be made to establish reimbursement policies that encourage the adoption of endoscopic imaging systems.

The COVID-19 pandemic had a significant impact on the global healthcare system, and endoscopic procedures were no exception. During the initial phase of the pandemic, non-emergency procedures were delayed or canceled to reduce the risk of infection. This led to a decline in the adoption rate of endoscopic imaging systems. However, as the situation improves and healthcare systems recover, the adoption rate is expected to return to pre-pandemic levels.

Despite the potential challenges, the demand for endoscopic procedures is expected to continue growing due to the increasing need for minimally invasive procedures and shorter recovery periods. With the proper measures in place, such as addressing skill shortages and implementing reimbursement systems, the global endoscopic imaging systems market has significant potential for growth in the coming years.

---

Market Segmentation

---

The market is segmented based on various factors, including application and region.

Segmentation by Application
Therapeutic Endoscopic Imaging Systems
Diagnostic Endoscopic Imaging Systems – Hospitals, Ambulatory Surgical Centers (ASCs), and Clinics and Physician Offices

Segmentation by Region
North America: U.S., Canada
Asia-Pacific: Japan, South Korea, India, Rest-of-Asia-Pacific
Europe: Germany, France, U.K., Italy, Spain, Rest-of-Europe
Commonwealth of Independent States (CIS)
China
Latin America
Middle East and Africa

During the forecast period of 2022-2030, the diagnostic endoscopic imaging systems segment is expected to dominate the global endoscopic imaging systems market in terms of application. The market is segmented into the diagnostic endoscopic imaging systems market and therapeutic endoscopic imaging systems market. The diagnostic segment held the largest share in 2020 and is projected to continue this trend due to the presence of global and regional companies and a wider awareness of endoscopy’s diagnostic usage. On the other hand, the therapeutic segment is expected to be the fastest-growing segment in the market, with a projected CAGR of 6.12% during the forecast period.

In the diagnostic endoscopic imaging systems segment, the market has been further segmented by facility into hospitals, ambulatory surgical centers (ASCs), and clinics and physician offices. Hospitals held the largest share in 2021 and are anticipated to continue dominating the market during the forecast period. Additionally, the clinics and physician offices segment is expected to grow at the fastest rate, with a CAGR of 7.90% during the forecast period. Within hospitals, the market is further segmented into low, value, and premium cost endoscopic imaging systems. The value segment held the largest share in 2021 and is predicted to continue its dominance throughout the forecast period. Moreover, the low-cost segment is expected to grow at the fastest rate, with a projected CAGR of 7.26%.

North America currently holds the largest market share in terms of revenue generation. The North America endoscopic imaging systems market was valued at $1,080 million in 2021 and is projected to reach $1,823 million by 2030, with a CAGR of 6.00%. Factors such as the presence of advanced visualization devices and high reimbursement rates contribute to the growth of this market. Europe and Asia-Pacific follow North America in terms of market share, and both regions are expected to grow significantly during the forecast period, with projected CAGRs of 5.86% and 8.47%, respectively.

The growth of the North America endoscopic imaging systems market is driven by several factors, including the presence of global players, a growing geriatric population, and the adoption of minimally invasive procedures. The market is also fueled by various local and global companies operating through direct or indirect sales channels. Moreover, increased investments by public and private hospitals in North America for the implementation of advanced systems further contribute to market growth. The prevalence of chronic disorders is also a significant factor, as it leads to an increased volume of endoscopic procedures and subsequently drives market growth. For example, the U.S. Department of Health & Human Services reports a considerable increase in the proportion of the U.S. population suffering from multiple chronic conditions, which is expected to boost the demand for endoscopic imaging systems.

---

Competitive Landscape

---

The selection of profiled companies was based on inputs gathered from primary experts and an extensive analysis of their company coverage, product portfolio, and market penetration.

Key companies profiled in this report include Ambu A/S, Arthrex, Inc., B. Braun Melsungen AG, Boston Scientific Corporation, CONMED Corporation, Fujifilm Holdings Corporation, HOYA Corporation, Johnson & Johnson, KARL STORZ SE & Co. KG, Olympus Corporation, Richard Wolf GmbH, Smith & Nephew Plc, SonoScape Medical Corp., Stryker Corporation, Xion GmbH.

---

Recent Industry Developments

---

In October 2021, Fujifilm Healthcare Americas Corporation introduced its latest product, the El-740D/S dual-channel endoscope. This endoscope has received approval from the U.S. Food and Drug Administration (FDA) and is designed for use in both upper and lower gastrointestinal areas.

During August 2021, Boston Scientific Corporation obtained FDA approval for its Exalt B single-use bronchoscope.

In the same month of August 2021, KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG, unveiled an updated version of their TELE PACK+ compact endoscopy system. This new version enables connectivity with StreamConnect for networking and data management purposes.

Fujifilm Medical Systems U.S.A., Inc. achieved FDA approval for its ELUXEO Surgical System, an oxygen saturation endoscopic imaging system, in July 2021.

In June 2021, HOYA Corporation’s subsidiary PENTAX Medical entered into a joint venture partnership with Jiangsu Vedkang Medical Science and Technology. Together, they aim to produce single-use flexible medical endoscopic therapeutic products.

Boston Scientific Corporation received CE mark approval for its Exalt B single-use bronchoscope in May 2021.

Olympus Corporation launched a new line of endoscopes called H-SteriScopes in April 2021. This line includes five new single-use bronchoscopes.

In February 2021, Olympus Corporation acquired Quest Photonic Devices to expand its portfolio of endoscopy devices.

Ambu A/S partnered with a prominent U.S. Group Purchasing Organization (GPO) in October 2020 to collaborate on the development of single-use endoscopes for various medical specialties.

---

Key Questions Answered

---

What is the estimated market size for the global endoscopic imaging systems market by the conclusion of 2030?

Additionally, what is the projected global installed base of these systems by the conclusion of 2030?

How do regional regulations impact both the regional and global markets for endoscopic imaging systems?

What was the impact of the COVID-19 pandemic on the growth of the global market?

What is the trend of patent filings in the global endoscopic imaging systems market?

Which key companies have been involved in patent filing activities from 2019 to 2021?

Who are the major players in the global endoscopic imaging systems market?

What was the market share of these companies in 2021?

Which strategies do companies in the global endoscopic imaging systems market commonly adopt to strengthen their market presence?

What are the key market drivers and restraints influencing the global endoscopic imaging systems market? What is their impact in the short, medium, and long term?

What is the projected market size of diagnostic and therapeutic endoscopic imaging systems by the conclusion of 2030?

Furthermore, which segment is expected to have the highest compound annual growth rate (CAGR) during the forecast period of 2022-2030?

What is the pricing framework for endoscopic imaging systems in different regions?

How does this pricing framework influence the installed base in regional markets and subsequently impact their market size?

Which regional market is projected to have the highest CAGR during the forecast period of 2022-2030?